Jakafi 25 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FCZJ3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $50,372
Award facts
- Contract value 100% obligated
- $50,372.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,372.04 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 60 tablets of JAKAFI 25 mg. The contract is priced on a firm fixed-price basis with an ultimate completion date of January 28, 2026, and no set-aside designation was utilized. DMS Pharmaceutical Group was selected as the awardee based on its established capabilities as a regional prime vendor contractor within the DLA's pharmaceutical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) within the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide. The underlying PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, has a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As the sole awardee on this delivery order with no identified subcontractors, DMS Pharmaceutical Group demonstrates its capacity to fulfill specialized pharmaceutical requirements for military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FCZJ3?
SPE2DR26FCZJ3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FCZJ3 worth?
The government has obligated $50,372 on SPE2DR26FCZJ3.
Is contract SPE2DR26FCZJ3 an order under another contract?
Yes. SPE2DR26FCZJ3 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZJ3 competed?
The extent of competition for SPE2DR26FCZJ3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award